A Phase 1 interventional study of PF-06801591 and PF-06801591 in Part 1, MELANOMA and SCCHN, sponsored by Pfizer. Completed at 67 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-13.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Melanoma by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Melanoma · Pfizer.
Among the 52 studies in Melanoma by Pfizer, this one is the 15th largest by enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2016, is one of 27 in phase 1, and was the 23rd registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →1 of the 52 studies in Melanoma by Pfizer is open now, in 6 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, France, Netherlands and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 19 · Phase 3 3
First in 2002; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 40 across 2,650 interventional studies indexed under Melanoma.
Median enrollment 77 across the 48 interventional studies, 496 across the 2 observational. Of the 47 that completed or were terminated, 23 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Melanoma by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05355701PfizerA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Melanoma by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with locally advanced or metastatic melanoma, SCCHN, ovarian carcinoma, sarcoma, NSCLC, urothelial carcinoma or other solid tumors. This is a 2 Part study whereby the safety and tolerability of increasing dose levels of intravenous (IV) or subcutaneous (SC) PF-06801591 was assessed in Part 1. Part 2 expansion is designed to further evaluate the safety and efficacy of SC PF-06801591 in patients with NSCLC or urothelial carcinoma as well as confirm the recommended Phase 2 dose.
Protocol B8011001 is a Phase 1, two part, open-label, multi center, multiple-dose, safety, efficacy, PK, and PD study of PF-06801591 administered intravenously (IV) or subcutaneous (SC) in previously treated adult patients with locally advanced or metastatic melanoma, squamous cell carcinoma head and neck (SCCHN), ovarian carcinoma, sarcoma, non-small cell lung carcinoma (NSCLC), urothelial carcinoma or other solid tumors.
The first part of the study, Part 1 dose escalation, was designed to assess the safety and tolerability of increasing dose levels of IV or SC administered PF-06801591 to establish the maximum tolerated dose (MTD) using a modified Toxicity Probability Interval (mTPI) design. Part 2 expansion is designed to further evaluate the safety and efficacy of 300 mg of PF-06801591 administered SC once every 4 weeks in patients with NSCLC or urothelial carcinoma as well as confirm the recommended Phase 2 dose (RP2D). Part 1 enrollment has completed, enrollment will only be allowed for Part 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (Part 2 Only)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.5 mg/kg IV every 21 days (Part 1)
Drug: PF-06801591
1.0 mg/kg IV every 21 days (Part 1)
Drug: PF-06801591
3.0 mg/kg IV every 21 days (Part 1)
Drug: PF-06801591
10 mg/kg IV every 21 days (Part 1)
Drug: PF-06801591
300 mg SC every 28 days (Part 1 and 2)
Drug: PF-06801591
IV every 21 days (Part 1)
300 mg SC every 28 days (Part 1 and 2)
Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1
DLT was defined as any of the following drug-related adverse events (AEs) occurring during the first cycle (21 days for IV dosing, 28 days for SC dosing) in Part 1: Grade 5 AE; Grade 4 neutropenia lasting \>5 days from initiation of granulocyte colony stimulating factor; Grade 4 thrombocytopenia with bleeding; Platelet transfusion requirement or a platelet count \<10,000/uL; Grade 4 non-hematologic AE; Grade 3 AE lasting \>7 days despite optimal supportive care; Grade 3 central nervous system AE regardless of duration; met criteria for drug induced liver injury. Severity of AEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.
Time frame: Cycle 1 in Part 1 (21 days for IV administration of PF-06801591; 28 days for SC administration of PF-06801591)
Number of Participants With All-Causality Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2
AE = any untoward medical occurrence in participant who received study treatment without regard to possibility of causal relationship. Treatment-emergent events = between first dose of study treatment and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grades of severity were defined by CTCAE v4.03. Grades of severity were defined by CTCAE v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.
Time frame: Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)
Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2
Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-emergent events = between first dose of study treatment and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-related AEs and SAEs were determined by the investigator. Grades of severity were defined by CTCAE v4.03. Grades of severity were defined by CTCAE v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.
Time frame: Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)
Number of Participants With Laboratory Test Abnormalities - Part 1 and Part 2
Following parameters were analyzed for laboratory examination: hematology (anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased); chemistries (increase of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood bilirubin, CPK, creatinine, gamma-glutamyl transferase \[GGT\], lipase, and serum amylase); urinalysis (proteinuria); coagulation (activated partial thromboplastin time prolonged, international normalized ratio \[INR\] increased). Grades of severity were defined by CTCAE v4.03. Grade 0 = No Change from normal or reference range (this grade is not included in the CTCAE v4.03 document but may used in certain circumstances). Grade 1 = mild adverse event (AE). Grade 2 = moderate AE; Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.
Time frame: Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)
Objective Response Rate (ORR) Based on RECIST Version 1.1 - Part 2
ORR was defined as percentage of participants with confirmed objective response (OR) of complete response (CR) and partial response (PR) based on RECIST version 1.1. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.
Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)
Objective Response Rate (ORR) Based on Immune Related RECIST (irRECIST) - Part 2
ORR was defined as percentage of participants with objective response (OR) of complete response (CR) and partial response (PR) based on irRECIST. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.
Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)
Maximum Plasma Concentration (Cmax) of PF-06801591 - Part 1
Cmax was the maximum concentration after dose administration observed directly from the data.
Time frame: Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1
AUClast of PF-06801591 in Part 1.
Area Under the Concentration Versus Time Curve (AUC) From Time Zero to the Last Quantifiable Time Point Prior to the Next Dose (AUClast) of PF-06801591 - Part 1
Time frame: Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1 in Part 1
Clearance (CL) of PF-06801591 - Part 1
CL for IV dosing. CL was calculated by dose / AUCtau for Cycles 1 and 4 IV dosing. AUCtau was defined as area under the serum concentration time profile from time zero to time tau, the dosing interval, where tau = 504 hours for every 3 weeks (Q3W) IV dosing reporting arm.
Time frame: Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1
Volume of Distribution at Steady State (Vss) of PF-06801591 - Part 1
Steady state volume of distribution of PF-0680159 for IV dosing. Vss was calculated by CL\*MRT. CL was the clearance for IV dosing. MRT was the mean residence time calculated for a single IV dose as AUMCinf/AUCinf - (DOF/2). AUMCinf was the area under the moment curve from time 0 extrapolated to infinity. DOF was the duration of infusion. AUCinf was the area under the serum concentration time profile from time 0 extrapolated to infinity.
Time frame: Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1
Accumulation Ratio (Rac) of PF-06801591 - Part 1
Rac was calculated by (Cycle 4 AUCtau) / (Cycle 1 AUCtau). AUCtau was Area under the serum concentration time profile from time zero to time tau, the dosing interval, where tau = 504 hours for Q3W IV dosing and tau = 672 hours for every 4 weeks (Q4W) SC dosing.
Time frame: Pre-dose and 1 hour post dose on Day 1 of Cycles 1 and 4 in Part 1
Terminal Elimination Half-Life (t1/2) of PF-06801591 - Part 1
t1/2 was calculated by Loge(2)/kel. kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.
Time frame: Pre-dose and 1 hour post dose on Day 1 of Cycles 1 and 4 in Part 1
Number of Participants With Anti-Drug Antibody (ADA) Against PF-06801591 - Part 1 and Part 2
Number of participants with ADA positive against PF-06801591 after IV and SC dosing - Part 1 and Part 2. A participant was ADA positive if (1) baseline titer was missing or negative and participant had ≥ 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a ≥ 0.602 in titer from baseline in ≥ 1 post-treatment sample (treatment-boosted). Participants who were ADA positive at baseline but did not become boosted post-treatment were considered as ADA negative.
Time frame: Baseline up to end of treatment (maximum of 851 days)
Number of Participants With Neutralizing Antibodies (NAb) Positive Against PF-06801591 - Part 1 and Part 2
Number of participants with NAb positive against PF-06801591 after IV and SC dosing - Part 1 and Part 2. A participant was NAb positive if (1) baseline titer was missing or negative and participant had ≥ 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a ≥ 0.602 in titer from baseline in ≥ 1 post-treatment sample (treatment-boosted). Participants who were NAb positive at baseline but did not become boosted post-treatment were considered as NAb negative.
Time frame: Baseline up to end of treatment (maximum of 851 days)
Percentage of Baseline PD-1 Receptor Occupancy (RO) by PF-06801591 - Part 1
PD-1 RO by sasanlimab was measured by the reduction of free receptor on the surface of CD8+ effector cells (CD3+, CD4-, CD8+, CD45RA+, CCR7-, CD279+) and CD8+ effector memory cells (CD3+, CD4-, CD8+, CD45RA-, CCR7-, CD279+) presented in pre- and postdose whole blood samples by flow cytometry. Percentage of baseline (ie, normalized change from baseline) PD-1 RO were calculated as \[(percentage of cells at Cycle X Day X)/(percentage of cells at baseline)\]\*100, and are reported for this outcome measure. Baseline was defined as the most recent non-missing value prior to dosing.
Time frame: Baseline, Days 1, 8, 15, 21 of Cycle 1, Day 1 of Cycles 2, 3, 5, Days 1, 15, 21 of Cycle 4, and end of treatment (EOT) in Part 1 (cycle = 21 days for IV dosing; cycle = 28 days for SC dosing)
Number of Participants Achieving Objective Response (OR) Based on RECIST Version 1.1 - Part 1
Number of participants achieving confirmed OR based on RECIST version 1.1 in Part 1. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.
Time frame: Baseline up to end of treatment in Part 1 (maximum of 1606 days)
Number of Participants Achieving Objective Response (OR) Based on irRECIST - Part 1
Number of participants achieving confirmed OR based on irRECIST in Part 1. OR = irCR + irPR. Overall immune related complete response (irCR) was defined as complete disappearance of all lesions (whether measurable or not) and no new lesions. All measurable lymph nodes also must have a reduction in short axis to \<10 mm. Overall immune related partial response (irPR) was defined as sum of the diameters (longest for non nodal lesions, shortest for nodal lesions) of target and new measurable lesions decreases \>=30%.
Time frame: Baseline up to end of treatment in Part 1 (maximum of 1606 days)
Progression-Free Survival (PFS) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2
PFS was defined as the time from initiation of study intervention to first documentation of tumor progression or to death due to any cause, whichever occurred first. PFS was analyzed by the Kaplan-Meier approach for each tumor type. As this outcome measure was a secondary endpoint defined in the protocol to investigate preliminary signal of efficacy, the results were analyzed and are reported for Part 1 dose-escalation groups combined to provide more statistically meaningful results, instead of results analyzed by dose level with very limited number of participants in each group.
Time frame: Baseline up to end of treatment (maximum of 1606 days)
Duration of Stable Disease (DOSD) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2
DOSD was analyzed by the Kaplan-Meier approach for each tumor type. Stable disease (SD) was defined as not qualifying for complete response (CR), partial response (PR), or progression. All target lesions must have been assessed. Stable could follow PR only in the rare case that the sum increased by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer held. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \< 10 mm). All target lesions must have been assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must have been assessed.
Time frame: Baseline up to end of treatment (maximum of 1606 days)
Duration of Response (DOR) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2
DOR was defined as the time from start date (which was the date of first documentation of PR or CR) to date of first documentation of objective progression or death. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. Objective progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. As this outcome measure was a secondary endpoint defined in the protocol to investigate preliminary signal of efficacy, the results were analyzed and are reported for Part 1 dose-escalation groups combined to provide more statistically meaningful results, instead of results analyzed by dose level with very limited number of participants in each group.
Time frame: Baseline up to end of treatment (maximum of 1606 days)
Time to Response (TTR) Based on RECIST Version 1.1 - Part 2
TTR was the time to confirmed or unconfirmed complete response (CR) or partial response (PR) based on investigator assessment per RECIST v1.1 by tumor type. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \< 10 mm). All target lesions must have been assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must have been assessed.
Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)
Time to Progression (TTP) Based on RECIST Version 1.1 and irRECIST - Part 2
TTP was the time to objective progression. Objective progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. TTP was analyzed by the Kaplan-Meier approach for each tumor type.
Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)
Median Time to Death - Part 2
Median time to death was analyzed by the Kaplan-Meier approach for each tumor type.
Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)
Probability of Survival at 6 Months, 1 Year, and 2 Years - Part 2
Probability of survival was calculated from the product-limit method.
Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)
Trough PF-06801591 Concentrations (Ctrough) - Part 2
Trough PF-06801591 Concentrations (Ctrough) - Part 2. Ctrough was directly observed from data.
Time frame: Pre-dose on Day 1 of Cycles 2-6, 9, 12, 15, 18, 21, 24, and Follow-up Day 28 in Part 2
| Milestone | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|---|---|---|---|---|
| Started | 2 | 8 | 8 | 7 | 15 | 68 | 39 |
| Treated | 2 | 8 | 8 | 7 | 15 | 68 | 38 |
| Completed | 1 | 0 | 2 | 1 | 2 | 10 | 5 |
| Not completed | 1 | 8 | 6 | 6 | 13 | 58 | 34 |
| Withdrew: Death | 1 | 6 | 5 | 6 | 9 | 32 | 21 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Participant refused further follow-up | 0 | 2 | 1 | 0 | 3 | 20 | 7 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 | 4 | 5 |
DLT was defined as any of the following drug-related adverse events (AEs) occurring during the first cycle (21 days for IV dosing, 28 days for SC dosing) in Part 1: Grade 5 AE; Grade 4 neutropenia lasting \>5 days from initiation of granulocyte colony stimulating factor; Grade 4 thrombocytopenia with bleeding; Platelet transfusion requirement or a platelet count \<10,000/uL; Grade 4 non-hematologic AE; Grade 3 AE lasting \>7 days despite optimal supportive care; Grade 3 central nervous system AE regardless of duration; met criteria for drug induced liver injury. Severity of AEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.
| Percentage of Participants | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) |
|---|---|---|---|---|---|
| Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1 | 0 | 0 | 0 | 0 | 0 |
AE = any untoward medical occurrence in participant who received study treatment without regard to possibility of causal relationship. Treatment-emergent events = between first dose of study treatment and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grades of severity were defined by CTCAE v4.03. Grades of severity were defined by CTCAE v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.
| Participants | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|---|---|---|---|---|
| Participants with AEs | 2 | 7 | 8 | 7 | 15 | 62 | 36 |
| Participants with SAEs | 1 | 3 | 3 | 3 | 3 | 18 | 13 |
| Participants with maximum Grade 3 or 4 AEs | 2 | 2 | 3 | 2 | 4 | 18 | 13 |
| Participants with maximum Grade 5 AEs | 0 | 1 | 1 | 2 | 0 | 8 | 5 |
Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-emergent events = between first dose of study treatment and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-related AEs and SAEs were determined by the investigator. Grades of severity were defined by CTCAE v4.03. Grades of severity were defined by CTCAE v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.
| Participants | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|---|---|---|---|---|
| Participants with AEs | 2 | 6 | 7 | 6 | 13 | 42 | 17 |
| Participants with SAEs | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Participants with maximum of Grade 3 or 4 AEs | 1 | 1 | 1 | 1 | 1 | 9 | 5 |
| Participants with maximum of Grade 5 AEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Following parameters were analyzed for laboratory examination: hematology (anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased); chemistries (increase of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood bilirubin, CPK, creatinine, gamma-glutamyl transferase \[GGT\], lipase, and serum amylase); urinalysis (proteinuria); coagulation (activated partial thromboplastin time prolonged, international normalized ratio \[INR\] increased). Grades of severity were defined by CTCAE v4.03. Grade 0 = No Change from normal or reference range (this grade is not included in the CTCAE v4.03 document but may used in certain circumstances). Grade 1 = mild adverse event (AE). Grade 2 = moderate AE; Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.
| Participants | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|---|---|---|---|---|
| ANEMIA — Grade 0 | 0 | 2 | 1 | 1 | 1 | 16 | 6 |
| ANEMIA — Grade 1 | 1 | 1 | 4 | 5 | 5 | 38 | 16 |
| ANEMIA — Grade 2 | 1 | 4 | 3 | 1 | 8 | 13 | 9 |
| ANEMIA — Grade 3 | 0 | 0 | 0 | 0 | 1 | 1 | 7 |
| ANEMIA — Grade 4 | NA | NA | NA | NA | NA | NA | NA |
| HEMOGLOBIN INCREASED — Grade 0 | 2 | 7 | 8 | 7 | 15 | 60 | 35 |
| HEMOGLOBIN INCREASED — Grade 1 | 0 | 0 | 0 | 0 | 0 | 7 | 3 |
| HEMOGLOBIN INCREASED — Grade 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| HEMOGLOBIN INCREASED — Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HEMOGLOBIN INCREASED — Grade 4 | NA | NA | NA | NA | NA | NA | NA |
| LYMPHOCYTE COUNT DECREASED — Grade 0 | 0 | 3 | 0 | 1 | 9 | 27 | 20 |
| LYMPHOCYTE COUNT DECREASED — Grade 1 | 0 | 0 | 2 | 1 | 2 | 21 | 11 |
| LYMPHOCYTE COUNT DECREASED — Grade 2 | 2 | 2 | 6 | 4 | 1 | 15 | 5 |
| LYMPHOCYTE COUNT DECREASED — Grade 3 | 0 | 1 | 0 | 1 | 3 | 5 | 2 |
| LYMPHOCYTE COUNT DECREASED — Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| LYMPHOCYTE COUNT INCREASED — Grade 0 | 2 | 7 | 8 | 7 | 14 | 63 | 37 |
| LYMPHOCYTE COUNT INCREASED — Grade 1 | NA | NA | NA | NA | NA | NA | NA |
| LYMPHOCYTE COUNT INCREASED — Grade 2 | 0 | 0 | 0 | 0 | 1 | 5 | 1 |
| LYMPHOCYTE COUNT INCREASED — Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LYMPHOCYTE COUNT INCREASED — Grade 4 | NA | NA | NA | NA | NA | NA | NA |
| NEUTROPHIL COUNT DECREASED — Grade 0 | 2 | 6 | 7 | 5 | 13 | 61 | 35 |
| NEUTROPHIL COUNT DECREASED — Grade 1 | 0 | 1 | 1 | 2 | 1 | 4 | 0 |
| NEUTROPHIL COUNT DECREASED — Grade 2 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| NEUTROPHIL COUNT DECREASED — Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| NEUTROPHIL COUNT DECREASED — Grade 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| PLATELET COUNT DECREASED — Grade 0 | 1 | 7 | 7 | 6 | 12 | 56 | 33 |
| PLATELET COUNT DECREASED — Grade 1 | 1 | 0 | 1 | 1 | 3 | 12 | 5 |
| PLATELET COUNT DECREASED — Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PLATELET COUNT DECREASED — Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PLATELET COUNT DECREASED — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WHITE BLOOD CELL DECREASED — Grade 0 | 1 | 5 | 5 | 3 | 10 | 62 | 34 |
| WHITE BLOOD CELL DECREASED — Grade 1 | 1 | 1 | 3 | 4 | 4 | 5 | 3 |
| WHITE BLOOD CELL DECREASED — Grade 2 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
| WHITE BLOOD CELL DECREASED — Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| WHITE BLOOD CELL DECREASED — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALANINE AMINOTRANSFERASE INCREASED — Grade 0 | 2 | 7 | 8 | 4 | 14 | 45 | 31 |
| ALANINE AMINOTRANSFERASE INCREASED — Grade 1 | 0 | 0 | 0 | 3 | 1 | 19 | 3 |
| ALANINE AMINOTRANSFERASE INCREASED — Grade 2 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| ALANINE AMINOTRANSFERASE INCREASED — Grade 3 | 0 | 0 | 0 | 0 | 0 | 3 | 1 |
| ALANINE AMINOTRANSFERASE INCREASED — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALKALINE PHOSPHATASE INCREASED — Grade 0 | 1 | 4 | 5 | 4 | 6 | 36 | 21 |
| ALKALINE PHOSPHATASE INCREASED — Grade 1 | 0 | 2 | 3 | 2 | 7 | 22 | 11 |
| ALKALINE PHOSPHATASE INCREASED — Grade 2 | 1 | 1 | 0 | 0 | 2 | 7 | 4 |
| ALKALINE PHOSPHATASE INCREASED — Grade 3 | 0 | 0 | 0 | 1 | 0 | 3 | 2 |
| ALKALINE PHOSPHATASE INCREASED — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ASPARTATE AMINOTRANSFERASE INCREASED — Grade 0 | 0 | 5 | 7 | 5 | 11 | 44 | 23 |
| ASPARTATE AMINOTRANSFERASE INCREASED — Grade 1 | 2 | 2 | 1 | 1 | 4 | 17 | 13 |
| ASPARTATE AMINOTRANSFERASE INCREASED — Grade 2 | 0 | 0 | 0 | 0 | 0 | 5 | 1 |
| ASPARTATE AMINOTRANSFERASE INCREASED — Grade 3 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| ASPARTATE AMINOTRANSFERASE INCREASED — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| BLOOD BILIRUBIN INCREASED — Grade 0 | 1 | 7 | 7 | 6 | 13 | 58 | 34 |
| BLOOD BILIRUBIN INCREASED — Grade 1 | 0 | 0 | 1 | 0 | 1 | 6 | 3 |
| BLOOD BILIRUBIN INCREASED — Grade 2 | 1 | 0 | 0 | 0 | 1 | 3 | 1 |
| BLOOD BILIRUBIN INCREASED — Grade 3 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| BLOOD BILIRUBIN INCREASED — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CPK INCREASED — Grade 0 | — | — | — | — | — | 3 | — |
| CPK INCREASED — Grade 1 | — | — | — | — | — | 0 | — |
| CPK INCREASED — Grade 2 | — | — | — | — | — | 0 | — |
| CPK INCREASED — Grade 3 | — | — | — | — | — | 0 | — |
| CPK INCREASED — Grade 4 | — | — | — | — | — | 0 | — |
| CREATININE INCREASED — Grade 0 | 0 | 0 | 3 | 0 | 13 | 58 | 2 |
| CREATININE INCREASED — Grade 1 | 1 | 6 | 4 | 7 | 1 | 6 | 30 |
| CREATININE INCREASED — Grade 2 | 1 | 1 | 1 | 0 | 1 | 3 | 5 |
| CREATININE INCREASED — Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| CREATININE INCREASED — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GGT INCREASED — Grade 0 | 0 | — | — | — | — | 0 | 0 |
| GGT INCREASED — Grade 1 | 1 | — | — | — | — | 2 | 1 |
| GGT INCREASED — Grade 2 | 0 | — | — | — | — | 1 | 0 |
| GGT INCREASED — Grade 3 | 0 | — | — | — | — | 1 | 1 |
| GGT INCREASED — Grade 4 | 0 | — | — | — | — | 0 | 0 |
| HYPERCALCEMIA — Grade 0 | 2 | 7 | 8 | 7 | 13 | 51 | 31 |
| HYPERCALCEMIA — Grade 1 | 0 | 0 | 0 | 0 | 1 | 15 | 5 |
| HYPERCALCEMIA — Grade 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| HYPERCALCEMIA — Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| HYPERCALCEMIA — Grade 4 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| HYPERGLYCEMIA — Grade 0 | 2 | 5 | 8 | 6 | 14 | 24 | 12 |
| HYPERGLYCEMIA — Grade 1 | 0 | 0 | 0 | 0 | 0 | 31 | 21 |
| HYPERGLYCEMIA — Grade 2 | 0 | 0 | 0 | 0 | 0 | 10 | 4 |
| HYPERGLYCEMIA — Grade 3 | 0 | 2 | 0 | 0 | 1 | 3 | 1 |
| HYPERGLYCEMIA — Grade 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| HYPERKALEMIA — Grade 0 | 2 | 6 | 7 | 7 | 15 | 48 | 27 |
| HYPERKALEMIA — Grade 1 | 0 | 0 | 1 | 0 | 0 | 8 | 6 |
| HYPERKALEMIA — Grade 2 | 0 | 0 | 0 | 0 | 0 | 11 | 3 |
| HYPERKALEMIA — Grade 3 | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| HYPERKALEMIA — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPERMAGNESEMIA — Grade 0 | 1 | 7 | 7 | 5 | 15 | 55 | 35 |
| HYPERMAGNESEMIA — Grade 1 | 1 | 0 | 1 | 2 | 0 | 6 | 3 |
| HYPERMAGNESEMIA — Grade 2 | NA | NA | NA | NA | NA | NA | NA |
| HYPERMAGNESEMIA — Grade 3 | 0 | 0 | 0 | 0 | 0 | 7 | 0 |
| HYPERMAGNESEMIA — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPERNATREMIA — Grade 0 | 2 | 5 | 8 | 6 | 13 | 51 | 35 |
| HYPERNATREMIA — Grade 1 | 0 | 2 | 0 | 1 | 2 | 8 | 2 |
| HYPERNATREMIA — Grade 2 | 0 | 0 | 0 | 0 | 0 | 7 | 0 |
| HYPERNATREMIA — Grade 3 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| HYPERNATREMIA — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| HYPOALBUMINEMIA — Grade 0 | 1 | 5 | 5 | 3 | 10 | 40 | 23 |
| HYPOALBUMINEMIA — Grade 1 | 0 | 2 | 2 | 4 | 2 | 18 | 11 |
| HYPOALBUMINEMIA — Grade 2 | 1 | 0 | 1 | 0 | 2 | 10 | 4 |
| HYPOALBUMINEMIA — Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| HYPOALBUMINEMIA — Grade 4 | NA | NA | NA | NA | NA | NA | NA |
| HYPOCALCEMIA — Grade 0 | 1 | 6 | 5 | 5 | 13 | 49 | 30 |
| HYPOCALCEMIA — Grade 1 | 1 | 1 | 3 | 2 | 1 | 12 | 7 |
| HYPOCALCEMIA — Grade 2 | 0 | 0 | 0 | 0 | 1 | 7 | 0 |
| HYPOCALCEMIA — Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPOCALCEMIA — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| HYPOGLYCEMIA — Grade 0 | 2 | 7 | 8 | 7 | 15 | 60 | 32 |
| HYPOGLYCEMIA — Grade 1 | 0 | 0 | 0 | 0 | 0 | 8 | 6 |
| HYPOGLYCEMIA — Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPOGLYCEMIA — Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPOGLYCEMIA — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPOKALEMIA — Grade 0 | 1 | 7 | 5 | 6 | 10 | 61 | 33 |
| HYPOKALEMIA — Grade 1 | NA | NA | NA | NA | NA | NA | NA |
| HYPOKALEMIA — Grade 2 | 1 | 0 | 3 | 1 | 4 | 7 | 3 |
| HYPOKALEMIA — Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| HYPOKALEMIA — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPOMAGNESEMIA — Grade 0 | 2 | 6 | 7 | 7 | 8 | 42 | 29 |
| HYPOMAGNESEMIA — Grade 1 | 0 | 1 | 1 | 0 | 5 | 14 | 8 |
| HYPOMAGNESEMIA — Grade 2 | 0 | 0 | 0 | 0 | 2 | 8 | 1 |
| HYPOMAGNESEMIA — Grade 3 | 0 | 0 | 0 | 0 | 0 | 4 | 0 |
| HYPOMAGNESEMIA — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPONATREMIA — Grade 0 | 0 | 4 | 7 | 5 | 8 | 45 | 25 |
| HYPONATREMIA — Grade 1 | 0 | 2 | 1 | 1 | 5 | 19 | 10 |
| HYPONATREMIA — Grade 2 | NA | NA | NA | NA | NA | NA | NA |
| HYPONATREMIA — Grade 3 | 2 | 0 | 0 | 1 | 2 | 3 | 2 |
| HYPONATREMIA — Grade 4 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| HYPOPHOSPHATEMIA — Grade 0 | 1 | 5 | 6 | 7 | 15 | 56 | 27 |
| HYPOPHOSPHATEMIA — Grade 1 | 0 | 0 | 0 | 0 | 0 | 3 | 7 |
| HYPOPHOSPHATEMIA — Grade 2 | 1 | 2 | 2 | 0 | 0 | 7 | 4 |
| HYPOPHOSPHATEMIA — Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| HYPOPHOSPHATEMIA — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LIPASE INCREASED — Grade 0 | 2 | 4 | 5 | 7 | 13 | 50 | 23 |
| LIPASE INCREASED — Grade 1 | 0 | 3 | 1 | 0 | 0 | 11 | 7 |
| LIPASE INCREASED — Grade 2 | 0 | 0 | 1 | 0 | 0 | 4 | 3 |
| LIPASE INCREASED — Grade 3 | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
| LIPASE INCREASED — Grade 4 | 0 | 0 | 0 | 0 | 1 | 2 | 1 |
| SERUM AMYLASE INCREASED — Grade 0 | 1 | 6 | 7 | 6 | 13 | 45 | 23 |
| SERUM AMYLASE INCREASED — Grade 1 | 1 | 1 | 1 | 0 | 1 | 16 | 10 |
| SERUM AMYLASE INCREASED — Grade 2 | 0 | 0 | 0 | 1 | 0 | 4 | 2 |
| SERUM AMYLASE INCREASED — Grade 3 | 0 | 0 | 0 | 0 | 1 | 3 | 3 |
| SERUM AMYLASE INCREASED — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PROTEINURIA — Grade 0 | 0 | 5 | 4 | 1 | 9 | 46 | 15 |
| PROTEINURIA — Grade 1 | 1 | 2 | 3 | 3 | 6 | 15 | 17 |
| PROTEINURIA — Grade 2 | 1 | 0 | 1 | 2 | 0 | 5 | 5 |
| PROTEINURIA — Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| PROTEINURIA — Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED — Grade 0 | 1 | 6 | 5 | 4 | 11 | 44 | 19 |
| ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED — Grade 1 | 1 | 1 | 3 | 3 | 4 | 19 | 15 |
| ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED — Grade 2 | 0 | 0 | 0 | 0 | 0 | 4 | 3 |
| ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED — Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED — Grade 4 | NA | NA | NA | NA | NA | NA | NA |
| INR INCREASED — Grade 0 | 2 | 5 | 6 | 4 | 12 | 39 | 31 |
| INR INCREASED — Grade 1 | 0 | 2 | 1 | 3 | 3 | 25 | 4 |
| INR INCREASED — Grade 2 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| INR INCREASED — Grade 3 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| INR INCREASED — Grade 4 | NA | NA | NA | NA | NA | NA | NA |
ORR was defined as percentage of participants with confirmed objective response (OR) of complete response (CR) and partial response (PR) based on RECIST version 1.1. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.
| Percentage | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|
| Objective Response Rate (ORR) Based on RECIST Version 1.1 - Part 2 | 16.4 (8.5 to 27.5) | 18.4 (7.7 to 34.3) |
ORR was defined as percentage of participants with objective response (OR) of complete response (CR) and partial response (PR) based on irRECIST. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.
| Percentage of Participants | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|
| Objective Response Rate (ORR) Based on Immune Related RECIST (irRECIST) - Part 2 | 19.4 (10.8 to 30.9) | 21.1 (9.6 to 37.3) |
Cmax was the maximum concentration after dose administration observed directly from the data.
| ug/mL | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | NA ± NA | 21.52 ± 23 | 69.63 ± 28 | 217.2 ± 36 | 21.24 ± 50 |
| Cycle 4 Day 1 | NA ± NA | 30.10 ± 16 | 86.34 ± 52 | 402.6 ± 42 | 56.48 ± 29 |
Area Under the Concentration Versus Time Curve (AUC) From Time Zero to the Last Quantifiable Time Point Prior to the Next Dose (AUClast) of PF-06801591 - Part 1
| ug*hr/mL | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) |
|---|---|---|---|---|---|
| AUClast of PF-06801591 in Part 1. | NA ± NA | 4700 ± 41 | 14770 ± 27 | 46780 ± 49 | 9923 ± 65 |
CL for IV dosing. CL was calculated by dose / AUCtau for Cycles 1 and 4 IV dosing. AUCtau was defined as area under the serum concentration time profile from time zero to time tau, the dosing interval, where tau = 504 hours for every 3 weeks (Q3W) IV dosing reporting arm.
| L/hr | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) |
|---|---|---|---|---|
| Cycle 1 Day 1 | — | NA ± NA | — | — |
| Cycle 4 Day 1 | NA ± NA | NA ± NA | 0.006045 ± 57 | 0.004984 ± 14 |
Steady state volume of distribution of PF-0680159 for IV dosing. Vss was calculated by CL\*MRT. CL was the clearance for IV dosing. MRT was the mean residence time calculated for a single IV dose as AUMCinf/AUCinf - (DOF/2). AUMCinf was the area under the moment curve from time 0 extrapolated to infinity. DOF was the duration of infusion. AUCinf was the area under the serum concentration time profile from time 0 extrapolated to infinity.
| L | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) |
|---|---|---|---|---|
| Cycle 1 Day 1 | — | NA ± NA | — | — |
Rac was calculated by (Cycle 4 AUCtau) / (Cycle 1 AUCtau). AUCtau was Area under the serum concentration time profile from time zero to time tau, the dosing interval, where tau = 504 hours for Q3W IV dosing and tau = 672 hours for every 4 weeks (Q4W) SC dosing.
| Ratio | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) |
|---|---|---|---|---|---|
| Accumulation Ratio (Rac) of PF-06801591 - Part 1 | NA ± NA | NA ± NA | NA ± NA | 2.360 ± 12 | 2.073 ± 31 |
t1/2 was calculated by Loge(2)/kel. kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.
| Days | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | NA ± NA | — | — | — |
| Cycle 4 Day 1 | — | — | — | — | NA ± NA |
Number of participants with ADA positive against PF-06801591 after IV and SC dosing - Part 1 and Part 2. A participant was ADA positive if (1) baseline titer was missing or negative and participant had ≥ 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a ≥ 0.602 in titer from baseline in ≥ 1 post-treatment sample (treatment-boosted). Participants who were ADA positive at baseline but did not become boosted post-treatment were considered as ADA negative.
| Participants | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) |
|---|---|---|---|---|---|---|---|
| Number of Participants With Anti-Drug Antibody (ADA) Against PF-06801591 - Part 1 and Part 2 | 1 | 5 | 3 | 1 | 1 | 0 | 0 |
Number of participants with NAb positive against PF-06801591 after IV and SC dosing - Part 1 and Part 2. A participant was NAb positive if (1) baseline titer was missing or negative and participant had ≥ 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a ≥ 0.602 in titer from baseline in ≥ 1 post-treatment sample (treatment-boosted). Participants who were NAb positive at baseline but did not become boosted post-treatment were considered as NAb negative.
| Participants | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) |
|---|---|---|---|---|---|---|---|
| Number of Participants With Neutralizing Antibodies (NAb) Positive Against PF-06801591 - Part 1 and Part 2 | 0 | 3 | 1 | 0 | 0 | 0 | 0 |
PD-1 RO by sasanlimab was measured by the reduction of free receptor on the surface of CD8+ effector cells (CD3+, CD4-, CD8+, CD45RA+, CCR7-, CD279+) and CD8+ effector memory cells (CD3+, CD4-, CD8+, CD45RA-, CCR7-, CD279+) presented in pre- and postdose whole blood samples by flow cytometry. Percentage of baseline (ie, normalized change from baseline) PD-1 RO were calculated as \[(percentage of cells at Cycle X Day X)/(percentage of cells at baseline)\]\*100, and are reported for this outcome measure. Baseline was defined as the most recent non-missing value prior to dosing.
| Percentage of Baseline | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.1) | 0.56 (0.0 to 4.0) | 0.02 (0.0 to 0.6) | 0.32 (0.0 to 3.0) |
| Cycle 1 Day 8 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.2) | 0.00 (0.0 to 1.4) | 0.00 (0.0 to 3.1) |
| Cycle 1 Day 15 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 1.3) | 0.00 (0.0 to 0.6) | 0.00 (0.0 to 7.7) | 0.57 (0.0 to 4.5) |
| Cycle 1 Day 21 | — | — | — | — | 0.00 (0.0 to 1.0) |
| Cycle 2 Day 1 | 1.48 (0.0 to 3.0) | 0.04 (0.0 to 1.7) | 0.82 (0.0 to 3.0) | 0.00 (0.0 to 1.0) | 0.00 (0.0 to 4.7) |
| Cycle 3 Day 1 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.2) | 0.47 (0.0 to 3.1) | 0.00 (0.0 to 2.3) | 0.00 (0.0 to 4.7) |
| Cycle 4 Day 1 | 0.80 (0.5 to 1.1) | 0.00 (0.0 to 0.0) | 0.05 (0.0 to 23.2) | 0.00 (0.0 to 2.1) | 0.00 (0.0 to 2.1) |
| Cycle 4 Day 15 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 2.6) | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.7) | 0.00 (0.0 to 1.4) |
| Cycle 4 Day 21 | — | — | — | — | 1.31 (0.0 to 1.4) |
| Cycle 5 Day 1 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 3.2) | 0.00 (0.0 to 1.2) | 0.00 (0.0 to 1.5) |
| EOT | — | 0.00 (0.0 to 0.5) | 0.00 (0.0 to 0.7) | 0.00 (0.0 to 0.5) | 0.17 (0.0 to 2.7) |
Number of participants achieving confirmed OR based on RECIST version 1.1 in Part 1. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.
| Participants | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) |
|---|---|---|---|---|---|
| Number of Participants Achieving Objective Response (OR) Based on RECIST Version 1.1 - Part 1 | 1 | 2 | 1 | 2 | 1 |
Number of participants achieving confirmed OR based on irRECIST in Part 1. OR = irCR + irPR. Overall immune related complete response (irCR) was defined as complete disappearance of all lesions (whether measurable or not) and no new lesions. All measurable lymph nodes also must have a reduction in short axis to \<10 mm. Overall immune related partial response (irPR) was defined as sum of the diameters (longest for non nodal lesions, shortest for nodal lesions) of target and new measurable lesions decreases \>=30%.
| Participants | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) |
|---|---|---|---|---|---|
| Number of Participants Achieving Objective Response (OR) Based on irRECIST - Part 1 | 1 | 2 | 1 | 2 | 1 |
PFS was defined as the time from initiation of study intervention to first documentation of tumor progression or to death due to any cause, whichever occurred first. PFS was analyzed by the Kaplan-Meier approach for each tumor type. As this outcome measure was a secondary endpoint defined in the protocol to investigate preliminary signal of efficacy, the results were analyzed and are reported for Part 1 dose-escalation groups combined to provide more statistically meaningful results, instead of results analyzed by dose level with very limited number of participants in each group.
| Months | Part 1: PF-06801591 0.5-10 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|---|---|
| RECIST v1.1 | 4.7 (1.4 to 8.3) | 3.0 (1.6 to 6.0) | 3.7 (1.9 to 5.5) | 2.9 (1.9 to 3.8) |
| irRECIST | 4.9 (1.4 to 13.8) | 4.5 (1.9 to 13.7) | 5.5 (2.8 to 8.2) | 3.8 (2.0 to 14.5) |
DOSD was analyzed by the Kaplan-Meier approach for each tumor type. Stable disease (SD) was defined as not qualifying for complete response (CR), partial response (PR), or progression. All target lesions must have been assessed. Stable could follow PR only in the rare case that the sum increased by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer held. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \< 10 mm). All target lesions must have been assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must have been assessed.
| Months | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|---|---|---|---|---|
| RECIST v1.1 | NA | NA (4.6 to NA) | 24.3 (13.8 to 34.9) | 5.7 (2.5 to 8.8) | 6.0 (3.8 to 7.3) | 6.5 (3.7 to 10.1) | 8.5 (3.7 to NA) |
| irRECIST | NA | NA (4.6 to NA) | 29.0 (20.0 to 37.9) | 5.7 (2.5 to 8.8) | 13.7 (3.3 to 13.7) | 7.5 (5.4 to 18.4) | 14.5 (3.7 to NA) |
DOR was defined as the time from start date (which was the date of first documentation of PR or CR) to date of first documentation of objective progression or death. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. Objective progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. As this outcome measure was a secondary endpoint defined in the protocol to investigate preliminary signal of efficacy, the results were analyzed and are reported for Part 1 dose-escalation groups combined to provide more statistically meaningful results, instead of results analyzed by dose level with very limited number of participants in each group.
| Months | Part 1: PF-06801591 0.5-10 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|---|---|
| RECIST v1.1 | 9.7 (3.7 to NA) | NA | 21.8 (5.8 to NA) | 13.9 (3.8 to NA) |
| irRECIST | 13.0 (4.1 to NA) | NA | 22.1 (6.8 to NA) | NA (4.6 to NA) |
TTR was the time to confirmed or unconfirmed complete response (CR) or partial response (PR) based on investigator assessment per RECIST v1.1 by tumor type. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \< 10 mm). All target lesions must have been assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must have been assessed.
| Months | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|
| Time to Response (TTR) Based on RECIST Version 1.1 - Part 2 | 2.71 (1.4 to 12.0) | 2.33 (1.4 to 5.5) |
TTP was the time to objective progression. Objective progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. TTP was analyzed by the Kaplan-Meier approach for each tumor type.
| Months | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|
| RECIST v1.1 | 3.7 (1.9 to 5.7) | 3.7 (1.9 to 8.5) |
| irRECIST | 6.5 (3.7 to 10.3) | 8.5 (2.5 to 19.4) |
Median time to death was analyzed by the Kaplan-Meier approach for each tumor type.
| Months | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|
| Median Time to Death - Part 2 | 14.7 (7.1 to NA) | 10.9 (7.2 to 19.9) |
Probability of survival was calculated from the product-limit method.
| Probability | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|
| 6 Months | 0.773 (0.647 to 0.859) | 0.711 (0.527 to 0.833) |
| 1 Year | 0.547 (0.407 to 0.667) | 0.471 (0.290 to 0.633) |
| 2 Years | 0.403 (0.265 to 0.537) | 0.286 (0.127 to 0.467) |
Trough PF-06801591 Concentrations (Ctrough) - Part 2. Ctrough was directly observed from data.
| ug/mL | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC |
|---|---|---|
| Cycle 2 Day 1 | 14.97 ± 48 | 14.34 ± 73 |
| Cycle 3 Day 1 | 22.54 ± 37 | 20.15 ± 84 |
| Cycle 4 Day 1 | 23.55 ± 53 | 23.77 ± 60 |
| Cycle 5 Day 1 | 23.58 ± 41 | 19.32 ± 186 |
| Cycle 6 Day 1 | 29.67 ± 36 | 17.13 ± 249 |
| Cycle 9 Day 1 | 29.01 ± 36 | 29.88 ± 30 |
| Cycle 12 Day 1 | 34.29 ± 16 | 12.74 ± 770 |
| Cycle 15 Day 1 | 40.90 ± 22 | 22.10 ± 56 |
| Cycle 18 Day 1 | 35.09 ± 25 | 20.17 ± 75 |
| Cycle 21 Day 1 | 27.16 ± 25 | 22.11 ± 55 |
| Cycle 24 Day 1 | 30.81 ± 16 | 38.02 ± 38 |
| Follow-up Day 28 | 43.62 ± 33 | 35.17 ± 32 |
Collected over Baseline up to 28 days after last dose of study drug (up to a maximum of 237 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| Part 1: PF-06801591 1 mg/kg (IV) | 6/8 (75%) | 3/8 (37.5%) | 7/8 (87.5%) |
| Part 1: PF-06801591 3 mg/kg (IV) | 5/8 (62.5%) | 3/8 (37.5%) | 8/8 (100%) |
| Part 1: PF-06801591 10 mg/kg (IV) | 6/7 (85.7%) | 3/7 (42.9%) | 7/7 (100%) |
| Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | 10/15 (66.7%) | 3/15 (20%) | 15/15 (100%) |
| Part 1: PF-06801591 IV Total | 18/25 (72%) | 10/25 (40%) | 24/25 (96%) |
| Part 1: PF-06801591 IV and SC Total | 28/40 (70%) | 13/40 (32.5%) | 39/40 (97.5%) |
| Part 2: PF-06801591 300 mg (SC) for NSCLC | 33/68 (48.5%) | 18/68 (26.5%) | 59/68 (86.8%) |
| Part 2: PF-06801591 300 mg (SC) for UC | 21/38 (55.3%) | 13/38 (34.2%) | 33/38 (86.8%) |
| Part 2: PF-06801591 NSCLC and UC Total | 54/106 (50.9%) | 31/106 (29.2%) | 92/106 (86.8%) |
| Event | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 1: PF-06801591 IV Total | Part 1: PF-06801591 IV and SC Total | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC | Part 2: PF-06801591 NSCLC and UC Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/2 | 1/8 | 0/8 | 0/7 | 0/15 | 2/25 | 2/40 | 0/68 | 0/38 | 0/106 |
| Disease progressionGeneral disorders | 0/2 | 1/8 | 1/8 | 2/7 | 0/15 | 4/25 | 4/40 | 3/68 | 2/38 | 5/106 |
| Atrial fibrillationCardiac disorders | 0/2 | 0/8 | 0/8 | 1/7 | 0/15 | 1/25 | 1/40 | 0/68 | 0/38 | 0/106 |
| Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/2 | 0/8 | 0/8 | 1/7 | 0/15 | 1/25 | 1/40 | 0/68 | 0/38 | 0/106 |
| Intestinal obstructionGastrointestinal disorders | 0/2 | 1/8 | 0/8 | 0/7 | 0/15 | 1/25 | 1/40 | 0/68 | 0/38 | 0/106 |
| Small intestinal obstructionGastrointestinal disorders | 0/2 | 0/8 | 1/8 | 0/7 | 1/15 | 1/25 | 2/40 | 0/68 | 0/38 | 0/106 |
| Postoperative wound infectionInfections and infestations | 0/2 | 0/8 | 1/8 | 0/7 | 0/15 | 1/25 | 1/40 | 0/68 | 0/38 | 0/106 |
| DysphagiaGastrointestinal disorders | 0/2 | 0/8 | 0/8 | 0/7 | 1/15 | 0/25 | 1/40 | 1/68 | 0/38 | 1/106 |
| PneumoniaInfections and infestations | 0/2 | 0/8 | 0/8 | 0/7 | 1/15 | 0/25 | 1/40 | 1/68 | 0/38 | 1/106 |
| SepsisInfections and infestations | 0/2 | 0/8 | 0/8 | 0/7 | 1/15 | 0/25 | 1/40 | 0/68 | 1/38 | 1/106 |
| Event | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 1: PF-06801591 IV Total | Part 1: PF-06801591 IV and SC Total | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC | Part 2: PF-06801591 NSCLC and UC Total |
|---|---|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 2/2 | 4/8 | 2/8 | 3/7 | 2/15 | 11/25 | 13/40 | 2/68 | 4/38 | 6/106 |
| NauseaGastrointestinal disorders | 2/2 | 1/8 | 3/8 | 0/7 | 6/15 | 6/25 | 12/40 | 5/68 | 3/38 | 8/106 |
| VomitingGastrointestinal disorders | 2/2 | 2/8 | 2/8 | 1/7 | 5/15 | 7/25 | 12/40 | 1/68 | 0/38 | 1/106 |
| Generalised oedemaGeneral disorders | 2/2 | 3/8 | 4/8 | 4/7 | 5/15 | 13/25 | 18/40 | 0/68 | 0/38 | 0/106 |
| Mucosal inflammationGeneral disorders | 2/2 | 1/8 | 0/8 | 1/7 | 1/15 | 4/25 | 5/40 | 0/68 | 0/38 | 0/106 |
| Urinary tract infectionInfections and infestations | 2/2 | 0/8 | 1/8 | 1/7 | 2/15 | 4/25 | 6/40 | 2/68 | 5/38 | 7/106 |
| Blood creatinine increasedInvestigations | 2/2 | 1/8 | 1/8 | 0/7 | 2/15 | 4/25 | 6/40 | 3/68 | 3/38 | 6/106 |
| Decreased appetiteMetabolism and nutrition disorders | 2/2 | 3/8 | 1/8 | 0/7 | 7/15 | 6/25 | 13/40 | 9/68 | 3/38 | 12/106 |
| Back painMusculoskeletal and connective tissue disorders | 2/2 | 1/8 | 1/8 | 0/7 | 4/15 | 4/25 | 8/40 | 3/68 | 6/38 | 9/106 |
| HypothyroidismEndocrine disorders | 1/2 | 1/8 | 0/8 | 1/7 | 1/15 | 3/25 | 4/40 | 5/68 | 4/38 | 9/106 |
Baseline population included all enrolled participants who received at least 1 dose of study treatment. One participant who enrolled in Part 2: PF-06801591 300 mg (SC) for UC arm was not treated.
| Age, Customized(Participants) | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC | Total |
|---|---|---|---|---|---|---|---|---|
| 18-44 Years | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 4 |
| 45-64 Years | 1 | 3 | 5 | 3 | 10 | 28 | 16 | 66 |
| >=65 Years | 1 | 5 | 2 | 3 | 5 | 39 | 21 | 76 |
| Sex: Female, Male(Participants) | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 2 | 6 | 5 | 4 | 11 | 15 | 13 | 56 |
| Male | 0 | 2 | 3 | 3 | 4 | 53 | 25 | 90 |
| Race/Ethnicity, Customized(Participants) | Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV]) | Part 1: PF-06801591 1 mg/kg (IV) | Part 1: PF-06801591 3 mg/kg (IV) | Part 1: PF-06801591 10 mg/kg (IV) | Part 1: PF-06801591 300 mg (Subcutaneously [SC]) | Part 2: PF-06801591 300 mg (SC) for NSCLC | Part 2: PF-06801591 300 mg (SC) for UC | Total |
|---|---|---|---|---|---|---|---|---|
| White | 2 | 7 | 7 | 4 | 12 | 50 | 30 | 112 |
| Black or African American | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 3 |
| Asian | 0 | 0 | 0 | 2 | 1 | 18 | 8 | 29 |
| Other | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Feb 2016 to primary completion in Nov 2020, 57 months.
Results were first posted in Dec 2021, 1 year after primary completion.
Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 57 months is above that.
Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sasanlimab